Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

AB-201

Cell therapy (CAR-NK) · Kills target cells, directed at HER2 (ERBB2) · developed by Artiva Biotherapeutics

Phase 1/2 Most advanced trial (none active)

ARTV Developer

1 Registered trials

What is AB-201?

AB-201 is an allogeneic CAR-NK cell therapy derived from cord blood, genetically modified to express a chimeric antigen receptor targeting HER2. It is designed to recognize and kill HER2-expressing tumor cells. The drug is being studied in breast cancer, gastric cancer, and gastroesophageal junction adenocarcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Cell therapy (CAR-NK)
Targets: HER2 (ERBB2) (antigen)
Mechanism: Kills target cells, directed at HER2 (ERBB2)
Therapy area: Oncology
Developer: Artiva Biotherapeutics, Inc. (ARTV)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII: 3TTT9ZD93F

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05678205	Phase 1/2	Breast Cancer	Withdrawn	ARTV

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Breast CancerGastric CancerGastroesophageal Junction Adenocarcinoma

Other drugs acting on ERBB2

Neratinib FDA approved Trastuzumab Deruxtecan FDA approved Trastuzumab Emtansine FDA approved Zanidatamab FDA approved ADCT-502 Phase 1 BH-30643 Phase 1/2 CGT4255 Phase 1 CUDC-101 Phase 1 ELVN-002 Phase 1 Enozertinib Phase 1/2 NVL-330 Phase 1 TTX-MC138 Phase 1/2

Sources

NCI Thesaurus

Updated Oct 3, 2026. Something wrong or missing? Report it on the ARTV page.

Follow ARTV, the company behind AB-201

See ARTV's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ARTV catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z